AREVA, NCI to develop radiopharmaceutical drug
AREVA, with support from AEC Partners, has signed a cooperative research and development agreement with the National Cancer Institute (NCI) to develop a new treatment to fight cancer.
As part of the agreement, the Bethesda, Md.-based AREVA said it will provide medical quality lead-212 to the NCI for the design of a new radiopharmaceutical drug.
Until recently, lead-212 was considered a scarce radioactive element, but is now figuring in promising research on treatment for certain cancers for which the current arsenal of therapies has only limited results, AREVA said.
As part of the agreement, the Bethesda, Md.-based AREVA said it will provide medical quality lead-212 to the NCI for the design of a new radiopharmaceutical drug.
Until recently, lead-212 was considered a scarce radioactive element, but is now figuring in promising research on treatment for certain cancers for which the current arsenal of therapies has only limited results, AREVA said.